within Pharmacolibrary.Drugs.ATC.S;

model S01GX07
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 9.722222222222221e-06,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,
    adminCount     = 1,
    Vd             = 0.0145,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Azelastine</td></tr><tr><td>ATC code:</td><td>S01GX07</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Azelastine is a potent second-generation antihistamine with additional anti-inflammatory effects, used mainly for the treatment of allergic conjunctivitis and allergic rhinitis. It is currently approved for ophthalmic and intranasal use globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following ophthalmic administration.</p><h4>References</h4><ol><li><p>Simons, FE, &amp; Simons, KJ (1999). Clinical pharmacology of new histamine H1 receptor antagonists. <i>Clinical pharmacokinetics</i> 36(5) 329â€“352. DOI:<a href=\"https://doi.org/10.2165/00003088-199936050-00003\">10.2165/00003088-199936050-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10384858/\">https://pubmed.ncbi.nlm.nih.gov/10384858</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>"
  ));
end S01GX07;
